
## PsoMOT2019

Psoriasis Management of patients Over Time

**November 15<sup>th</sup> – 17<sup>th</sup> 2019** Amsterdam, The Netherlands

The PsoMOT is an international meeting initiated and funded by Almirall and it is for healthcare professionals only. For Dutch participants the program will be submitted for accreditation by the Dutch Society for Dermatology and Venereology.



## PsoMOT2019

Psoriasis Management of patients Over Time

## Saturday 16<sup>th</sup> November 2019

| 08.15 - 08.30 | <b>Chairmen's welcome</b> Matthias Augustin, Germany & Diamant Thaçi, Germany                                     |  |  |
|---------------|---|--|--|
| 08.30 - 08.50 | Real-world evidence studies;<br>expectations vs. reality<br>Luigi Naldi, Italy                                    |  |  |
| 08.50 - 09.15 | Real-world evidence studies:<br>why bother when we have<br>Randomised Controlled Trials?<br>Esteban Daudén, Spain |  |  |
| 09.15 - 09.40 | Patient-reported outcomes in psoriasis:<br>Incorporating the voice of patients<br>Peter Weisenseel, Germany       |  |  |
| 09.40 - 10.00 | Question and answer discussion  |  |  |
| 10.00 - 10.30 | Coffee break  |  |  |
| 10.30 – 10.55 | New insights into the pathogenesis of psoriasis - or is it the same old story? Stefano Piaserico, Italy           |  |  |
| 10.55 – 11.20 | <b>Psoriasis - it is not just about the skin</b><br>Esteban Daudén, Spain   |  |  |
| 11.20 - 11.45 | The right therapy for the right patient at the right time Ulrich Mrowietz, Germany                                |  |  |
| 11.45 - 12.10 | Tildrakizumab - shaping safety for IL-23p19 class Diamant Thaçi, Germany  |  |  |
| 12.10 - 12.30 | Question and answer discussion  |  |  |
| 12.30 - 14.00 | Lunch   |  |  |
| 14.00 – 14.25 | <b>Defining moderate psoriasis</b> Ulrich Mrowietz, Germany   |  |  |
| 14.25 – 14.50 | Managing psoriasis with systemic<br>therapies<br>Wolf-Henning Boehncke, Switzerland                               |  |  |
|               |   |  |  |

| 14.50 – 15.15            | Long-term efficacy and safety<br>of Fumaric Acid Esters<br>Deepak Balak, The Netherlands |  |  |  |
|--------------------------|--|--|--|--|
| 15.15 – 15.35            | Question and answer discussion   |  |  |  |
| 15.35 – 16.00            | Coffee break   |  |  |  |
| 16.00 - 17.00            | Workshop 1   |  |  |  |
| Workshop ´               | Clinical cases: Oral systemics   |  |  |  |
| 17.00 – 18.00 Workshop 2 |  |  |  |  |
| Workshop 2               | Clinical cases: Biologics  |  |  |  |
|                          |  |  |  |  |

## Sunday 17th November 2019

| 09.00 - 09.30       | Masterclass on the new International<br>Psoriasis Council guidelines<br>Peter van de Kerkhof, The Netherlands |   |  |
|---------------------|---|---|--|
| 09.30 - 10.30       | Workshop  | 3   |  |
| Workshop 3          | 3   | 'Building' the moderate psoriasis patient                                     |  |
| 10.30 - 10.50       | Coffee bre  | ak  |  |
| 10.50 - 11.50       | The Great Debate  |   |  |
| The Great<br>Debate | 1   | Is IL-17 the master cytokine? Diamant Thaçi, Germany Stefano Piaserico, Italy |  |
| 11.50 – 12.15       | Conclusions and wrap-up Matthias Augustin & Diamant Thaçi   |   |  |

This program is subject to changes.

